The systemic immune-inflammation index is superior to predicting clinical remission and relapse for ulcerative colitis patients treated with vedolizumab
The SII performed better than NLR and PLR in predicting clinical remission and relapse for UC patients on VDZ therapy. Moreover, patients with high SII may relapse after VDZ treatment and should be treated with caution.
Authors
- Ailing Liu (ORCID: https://orcid.org/0000-0002-4848-8426)
- Jun Wu (ORCID: https://orcid.org/0009-0009-1081-4829)
- Run-Qiu Wang
- Yonghong Xu (ORCID: https://orcid.org/0000-0002-8428-0577)
- Jing Yan (ORCID: https://orcid.org/0000-0002-5264-8197)
- Pin Meng
Institutions
- Qingdao University (CN)
- Peking University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Peking University People's Hospital (CN)
- Qingdao Women and Children's Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-03-13
- DOI
- https://doi.org/10.3389/fmed.2025.1524307
- Citations
- 1
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.05